Department of Pathology & Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA, USA.
Division of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine, UCLA, Los Angeles, CA, USA; Broad Stem Cell Research Center, UCLA, Los Angeles, CA, USA; Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, CA, USA.
Cell Stem Cell. 2019 Mar 7;24(3):376-389.e8. doi: 10.1016/j.stem.2018.12.011. Epub 2019 Jan 17.
The ability to generate T cells from pluripotent stem cells (PSCs) has the potential to transform autologous T cell immunotherapy by facilitating universal, off-the-shelf cell products. However, differentiation of human PSCs into mature, conventional T cells has been challenging with existing methods. We report that a continuous 3D organoid system induced an orderly sequence of commitment and differentiation from PSC-derived embryonic mesoderm through hematopoietic specification and efficient terminal differentiation to naive CD3CD8αβ and CD3CD4 conventional T cells with a diverse T cell receptor (TCR) repertoire. Introduction of an MHC class I-restricted TCR in PSCs produced naive, antigen-specific CD8αβ T cells that lacked endogenous TCR expression and showed anti-tumor efficacy in vitro and in vivo. Functional assays and RNA sequencing aligned PSC-derived T cells with primary naive CD8 T cells. The PSC-artificial thymic organoid (ATO) system presented here is an efficient platform for generating functional, mature T cells from human PSCs.
从多能干细胞(PSCs)中生成 T 细胞的能力有可能通过促进通用的现成细胞产品来改变自体 T 细胞免疫疗法。然而,现有的方法使人类 PSCs 分化为成熟的常规 T 细胞具有挑战性。我们报告称,连续的 3D 类器官系统通过造血特化和高效的终末分化,从 PSC 衍生的胚胎中胚层诱导出有序的定向程序从 CD3CD8αβ 和 CD3CD4 常规 T 细胞具有多样化的 T 细胞受体(TCR)库。在 PSCs 中引入 MHC 类 I 受限的 TCR 产生了幼稚的、抗原特异性的 CD8αβ T 细胞,这些细胞缺乏内源性 TCR 表达,并在体外和体内显示出抗肿瘤功效。功能测定和 RNA 测序将 PSC 衍生的 T 细胞与原代幼稚 CD8 T 细胞进行了对齐。本文介绍的 PSC-人工胸腺类器官(ATO)系统是从人 PSCs 中生成功能性成熟 T 细胞的有效平台。